Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225946 · ClinicalTrials.gov registry record · Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 3 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 3
Development phase
800
Enrollment target
20
Study locations

NCT07225946: Recruiting Phase 3 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Janssen Research & Development.

NCT07225946 is a Phase 3 study of Prostatic Neoplasms, Castration-Resistant that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 800 participants, above the 661-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225946, a Phase 3 study of Prostatic Neoplasms, Castration-Resistant, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 3
Development phase
800 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Primary Outcome

rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first.

Conditions Studied

Prostatic Neoplasms, Castration-Resistant

Interventions

  • DRUG Docetaxel
  • DRUG Prednisone
  • DRUG Pasritamig

Study Locations (20)

California

  • Valkyrie Clinical Trials - Los Angeles
  • Kaiser Permanente Southern California - Riverside

Colorado

  • Grand Valley Oncology - Grand Junction
  • Colorado Clinical Research - Lakewood

Minnesota

  • HealthPartners Frauenshuh Cancer Center CRC West - Saint Louis Park
  • HealthPartners Cancer Center at Regions Hospital CRC East - Saint Paul

Washington

  • Fred Hutch Cancer Center Sloan Clinic 2 - Seattle
  • Fred Hutchinson Cancer Research Center - Seattle

Arkansas

  • Arkansas Urology - Little Rock

Illinois

  • Duly Health and Care - Lisle

Kansas

  • Cancer Center of Kansas Heritage Plaza Medical Building - Wichita

Louisiana

  • East Jefferson General Hospital - Metairie

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2025-12-19
Est. Completion 2029-07-20
Phase Phase 3
Janssen Research & Development

593 total trials

What NCT07225946 shows while recruiting

NCT07225946 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 661-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (21% higher).

The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT07225946 names 20 study sites across 16 states, led by California, Colorado, Minnesota.

Frequently Asked Questions

What is clinical trial NCT07225946 about?

NCT07225946 is a clinical study titled "A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with met...

What is the current status of trial NCT07225946?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-12-19. Estimated completion is 2029-07-20.

What conditions does trial NCT07225946 study?

This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.

What interventions are being tested in trial NCT07225946?

The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Pasritamig (DRUG).

Who is sponsoring clinical trial NCT07225946?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225946 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostatic Neoplasms, Castration-Resistant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07225946's enrollment target sits among peer trials

800 2nd of 10 the highest of 10 other Prostatic Neoplasms, Castration-Resistant trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostatic Neoplasms, Castration-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07225946

Source: ClinicalTrials.gov NCT07225946, the US trial registry maintained by the National Library of Medicine. NCT07225946 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.